NCT07840456
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07840456
Title Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial (InflammaSTOP)
Acronym InflammaSTOP
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Hospital, Basel, Switzerland
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU | CHE

Facility Status City State Zip Country Details
Universitätslklinikum Würzburg Würzburg Bavaria 97080 Germany Details
Universitätsmedizin Greifswald Greifswald Mecklenburg-Vorpommern 17475 Germany Details
Uniklinik Köln Cologne North Rhine-Westphalia 50937 Germany Details
Katholisches Krankenhaus Hagen Hagen North Rhine-Westphalia 58097 Germany Details
Asklepios Klinik St. Georg Hamburg Hamburg Schleswig-Holstein 20099 Germany Details
University Hospital Basel Basel Canton of Basel-City 4031 Switzerland Details
Seeland Cancer Center Biel Biel/Bienne Canton of Bern 2502 Switzerland Details
HOCH Health Ostschweiz Sankt Gallen Canton of St. Gallen 9007 Switzerland Details
Universitätsspital Zürich Zurich Canton of Zurich 8091 Switzerland Details
Ente Ospedaliero Cantonale Bellinzona Canton Ticino 6500 Switzerland Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field